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EDITORIAL REVIEW
Immunobiologic factors in the pathogenesis of renal
infection
Animal models of specific diseases have charac-
terized well the cellular and humoral basis of immu-
nity to many infectious diseases. This approach also
has allowed conceptual advances to be made in our
understanding of the immunobiology of renal infec-
tion, and both the local and systemic immune re-
sponses to infection have been studied in detail [1].
Experimentally induced Escherichia coli pyelone-
phritis has been shown to be associated with a
prompt and vigorous immune response, but despite
the production of both local and systemic antibody
directed against the 0 antigens of the invading orga-
nism, the infection is not eradicated [2].
In this review we present the thesis that the vigor-
ous antibody response to renal infection may be in-
appropriate as a host defense mechanism, and we
suggest that a more effective host immune response
may be mounted if the balance of the immune re-
sponse is altered to restore cell-mediated immune
function. Recent experiments have shown that the
responsiveness of thymus-derived lymphocytes is
markedly depressed by a suppressor cell population
arising during renal infection. There is experimental
evidence that immunomodulation may provide an
alternative therapeutic approach to the manage-
ment of renal infection and other selected infectious
diseases. This is discussed.
Role of specific antibody
A feature of the experimentally induced infection
that resembles renal infection in man is that, al-
though the unmanipulated urinary tract is remark-
ably resistant to a retrograde bacterial challenge,
once microorganisms have gained access to the in-
terstitium of the kidney rapid bacterial proliferation
occurs. The inability of the immune mechanisms of
the host to eradicate infection and limit the rate of
bacterial replication is unique to the kidney and is
still a poorly understood facet of the pathogenesis
of renal infection. One explanation proposes that
the K antigens of E. coli, considered to be virulence
factors in renal infection [3], induce systemic and
local antibody less consistently than do 0 antigens
[4]. A further explanation we have considered is
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that the specific antibody response is "immuno-
enhancing," implying that the antibody response is
organism or "invader" protective rather than host
protective [5]. This was proposed because it was
found that a number of the infected kidneys of
pyelonephritic animals treated with cyclophospha-
mide were sterile even though the animal was un-
able to mount an antibody response against the in-
vading pathogen [6]. Fewer microorganisms per-
sisted in kidneys of cyclophosphamide-treated
animals compared with untreated animals and, sur-
prisingly, the extent of bacterial elimination with
cyclophosphamide was greater than that achieved
with the use of 'appropriate" antibiotics, including
ampicillin and kanamycin. In recent experiments,
however, we have not been able to demonstrate di-
rectly an immunoenhancing effect of circulating
antibody (Fig. 1). In these studies, "enhancing"
antibody was present in rats treated with cyclo-
phosphamide but failed to prevent the fall in bacte-
rial numbers induced by cyclophosphamide. In con-
trast, Forget et al [7] have some evidence to suggest
that the antibody response to renal infection may be
immunoenhancing.
Cell-mediated immune mechanisms
Much of the experimental work on the biology of
renal infection has been directed to determine the
role of circulating antibody. The contribution of
cell-mediated immunity to host immune defenses
has, in contrast, been poorly studied. Satisfactory
laboratory procedures for the assessment of cell-
mediated immune function have not been available
for rodent lymphocytes, and this has restricted ef-
forts to quantitate in vitro T lymphocyte function.
This difficulty has been overcome recently [8], and
the in vitro response of T lymphocytes to specific
mitogens has now been used to determine the effect
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Fig. 1. Effect ofputative "enhancing" antibody on renal infection. One hundred forty-seven rats were divided into control, untreated
animals, cyclophosphamide-treated animals (100 mg/kg in a split dose administered on day 2 and 4 after challenge), animals with a titer
(mean, 1:2450) of "enhancing" antibody at the time of challenge, and a group with "enhancing" antibody but which had also been
treated with cyclophosphamide. "Enhancing" antibody was developed by the i.m. injection of 2 X 10a killed E. coli 075. The animals
were then left 4 weeks before being immunized again with I x 10 killed E. coIl 7 days before the initiation of infection. Representative
animals from all groups were killed at intervals up to 30 days after challenge, and the bacteriologic status of the kidney was determined.
has been shown that administration of nonviable an-
tigen also results in a decreased response of T lym-
phocytes to mitogens and that the depression ap-
pears to be mediated through an antigen-activated
suppressor cell [10]. Generation of a similar cell
population in pyelonephritic animals could account
for the depressed cell-mediated immune function;
experiments investigating this hypothesis have
shown clearly that the immune function of non-
responsive splenic lymphocytes from pyelonephrit-
ic animals can be restored if a population of sup-
pressor cells generated during renal infection is re-
moved [9].
Depressed cell-mediated immune mechanisms
occurring in the course of an infectious disease have
been observed previously [11-15], but the demon-
stration of a suppressor cell in the splenic lympho-
cyte population of pyelonephritic animals, capable
of suppressing the mitogenic responsiveness of nor-
mal lymphocytes [16], was the first report describ-
ing a biologic event that could account for this de-
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of cell-mediated immunity on renal infection. The
results of these experiments are of particular inter-
est. A marked suppression of the cell-mediated im-
mune response was found as early as 2 hours after
the induction of renal infection, with maximum sup-
pression of immune responsiveness occurring 48 to
72 hours after challenge. Ninety-nine percent of the
immune reactivity of the splenic T lymphocytes was
ablated during this peak period, and the loss of
functional activity coincided with the period of rap-
id bacterial replication in the kidney, reflecting the
ineffectiveness of local immune defense mecha-
nisms [9].
Suppressor cells in renal infection
Several biologic mechanisms could account for
the reduced immune capability of T lymphocytes in
pyelonephritis. We have sought to account for the
close temporal association between the rapid acqui-
sition of an infectious antigenic mass and the de-
pressed immune function. In related experiments, it
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pressed response. Suppressor cells occur in normal
individuals, but the balance maintained between the
stimulation of suppressor mechanisms and the
maintenance of an effective immune system by en-
dogenous microorganisms is such that cell-mediat-
ed immune responses are normally preserved. This
balance, however, is disturbed by an intense local
antigenic stimulation that occurs in renal and other
infections, and the depressed cell-mediated immu-
nity that follows is, we believe, an example of acti-
vation of the suppressor arm of the immune regula-
tory mechanism.
Another explanation for the susceptibility of re-
nal tissue to infection is that the cellular com-
ponents of the host's immune system are depressed
by the unique physiologic environment of the kid-
ney [17, 18]. Inactivation of complement-mediated
host immune mechanisms by renal tissue has also
been a long-standing thesis in the biology of renal
infection [19], but there are a number of reasons
why the postulated mechanism of inactivation of C4
by ammonia is unlikely to occur under physiologic
conditions [20]. Recent studies have confirmed that
exposure of normal serum to renal tissue in culture
did result in the rapid loss of complement but that
this was not due to ammonia production [21]. The
finding suggested that the biologic significance of
the inactivation of complement in vitro by renal tis-
sue may have been overestimated, and in contin-
uing experiments with complement-depleted ani-
mals it was possible to show that complement-medi-
ated host immune mechanisms are an important
component of the host's immune response in pyelo-
nephritis [22]. In view of the recent studies demon-
strating the generation of suppressor cells during
the course of renal infection, an alternative thesis
needs consideration: namely, that the ineffective
immune mechanisms in the kidney may result from
hyperstimulation of the immune mechanisms and
the subsequent depression of T lymphocyte func-
tion by suppressor cells.
'Inappropriate'' immune responses
The experimental data presented so far has estab-
lished that renal infection causes the immune sys-
tem to generate an active B lymphocyte response
but at the same time markedly depresses the im-
mune capability of the T lymphocytes. This pattern
of immune responsiveness is not uncommon, and
there is evidence that a vigorous response to an an-
tigenic challenge by the humoral immune system
may occur at the expense of the other immune
mechanisms [23]. A reciprocal immune response of
this type may be important in determining the out-
come of a bacterial challenge, particularly if the
suppressed response is an effective protective
mechanism for the host. Under these circum-
stances, the vigorous antibody response to renal in-
fection could be considered "inappropriate" in
terms of a host defense mechanism, and, in theory,
a more effective immune response by the host could
be generated if the balance of the immune response
was altered to restore depressed cell-mediated im-
mune functions at the expense of a reduced specific
antibody response.
Although the inappropriate response" is the ex-
planation that we favor currently, other ex-
planations are equally tenable. For example, the
mammalian host has a range of immune mecha-
nisms that enables it to cope with challenges from a
wide variety of infectious agents, and the problem
faced by the host is how to select an appropriate
response that will limit the specific microbe's repli-
cation and eventually eradicate the pathogen. The
most effective mechanism for eliminating invasive
extracellular Gram-negative bacilli is antibody-pro-
moted phagocytosis, and the host may thus have
developed an "inverted" response in which cell-
mediated immune response is depressed to reduce
the inflammatory response and ultimately the struc-
tural damage to the kidney [16].
Immunomodulation with cyclophosphamide
If the immunobiology of renal infection follows
the course proposed and the hypothesis linking de-
pressed cell-mediated immune responses with the
period of rapid bacterial replication and the genera-
tion of an active suppressor cell is correct, it should
be possible to modify the course of renal infection
(and other selected infectious diseases where anti-
body responses are not effective). This could be
done with agents that modulate the activity of the
suppressor cells either directly or indirectly and re-
store cell-mediated immune responses. There is evi-
dence that cyclophosphamide is effective in enhanc-
ing cell-mediated immune responses, and because
the drug causes prolonged T-cell-mediated delayed-
type-hypersensitivity (DTH) reactions [24, 25], the
phenomenon has been studied extensively.
Originally it was suggested that the enhanced
cell-mediated immune response was due to inhibi-
tion of antibody production and lack of antigen anti-
body complexes, which were believed to inhibit de-
layed-type hypersensitivity [26]. Askenase, Hay-
den, and Gershon [27] subsequently presented
evidence that the enhancement of the DTH reaction
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by cyclophosphamide resulted from elimination of
suppressor cells sensitive to cyclophosphamide.
Similar results have been reported by Rollinghoff et
al [28], Mitsuoka, Baba, and Morikaw [29], Gill and
Liew [30], and Liew and Chan-Liew [31] and sup-
port the "deletion concept" that cyclophosphamide
acts by eliminating a suppressor cell, which, in turn,
depresses T lymphocyte function.
Ramshaw, Bretscher, and Parish [32, 33] have
proposed a third mechanism for the depression of
cell-mediated immune responses to some antigens,
suggesting that a T lymphocyte repressor cell is re-
sponsible. Under conditions where antibody is pro-
duced, helper T cells collaborating with B lympho-
cytes in the synthesis of antibody are responsible
for depressing cell-mediated immune response. The
situation is reversed by cyclophosphamide adminis-
tration, which leads to the generation of a repressor
T lymphocyte population, which modulates the
function of the helper T cells so that antibody pro-
duction is depressed, but at the same time cell-me-
diated immune responses, relieved of suppression,
are restored. Both the suppressor-cell "deletion"
and the repressor-cell theories suggest that the "in-
appropriate" response to renal infection is ame-
nable to immune manipulation by using cyclophos-
phamide, which could invert the balance of the im-
mune response and at the expense of reduced
production of circulating antibody restore cell-me-
diated immune function.
To test these hypotheses, we have reexamined
the effect of cyclophosphamide in pyelonephritic
rats using cyclophosphamide as an immuno-
modulator to alter the activity of a suppressor cell
population. The results (Fig. 2) confirm and extend
the original observations by showing a highly signif-
icant difference in the bacteriologic status of the
kidney in cyclophosphamide-treated and control
animals. These results are not unique, for other in-
fectious diseases have responded favorably to treat-
ment with cyclophosphamide. Ascher, Parker, and
Turk [34] treated guinea pigs with cyclophospha-
mide before immunization with killed tularemia
vaccine in Freund's incomplete adjuvant. This
caused prolonged and intensified DTH reaction
with in vitro lymphocyte transformation to tula-
remia antigen. The increased intensity was depen-
dent on the dose of bacterial antigen, but potentia-
tion of cell-mediated immunity to tularemia was
more prolonged than that seen with other protein
antigens. In another study, mice treated with cyclo-
phosphamide to reduce circulating antibody had a
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Fig. 2. Effect of cyclophosphamide on the bacteriologic status of the kidney in renal infection. Pyelonephritis was established in 97
animals, half of which were treated with cyclophosphamide (100 mg/kg in a split dose administered on days 2 and 4 after challenge).
Representative animals from the untreated control group and the cyclophosphamide-treated group were then killed at intervals, and the
bacteriologic status of the kidneys was determined.
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lower mortality when challenged with PR8 in-
fluenza virus [35]. The outcome of an infection can-
not thus be predicted solely by the levels of virus
neutralizing antibody. Similar results were obtained
in mice challenged with Listeria monocyto genes,
where cyclophosphamide administration allowed a
10,000-fold reduction in the immunizing dose of mi-
croorganisms necessary to protect mice against a
challenge with viable Listeria monocytogenes [36].
Immunomodulation as a potential therapeutic approach
These observations raise several interesting pros-
pects for the management of infectious diseases, in-
cluding renal infection, in which the immune re-
sponse appears "inappropriate" [37] and treatment
with antibiotics frequently unsuccessful. The dual
activity of cyclophosphamide as an immuno-
suppressive agent and as an immunomodulator has
been recognized by experimental immunologists for
some time, and in the experiments described it is
likely that the immunomodulating properties were
responsible for the effect of cyclophosphamide on
the bacteriologic course of infection in the pyelo-
nephritic kidney. The clinical use of cyclophospha-
mide, as an immunomodulator in infectious disease,
is limited on account of its associated immuno-
suppressive activity, but we believe its immuno-
modulatory effect on the course of renal infection
can be viewed as a prototype for immunomodulat-
ing agents that act at a specific point of cell inter-
action to either block suppressor activity directly or
through the induction of a repressor cell capable it-
self of blocking the activity of the suppressor cell.
The concept of an "inappropriate immune re-
sponse," where a suppressor cell-induced depres-
sion of cell-mediated immune responses leads to an
increased susceptibility of renal tissue to infection,
is a speculative interpretation of the existing experi-
mental data and is amenable to further evaluation.
Proposals that the more effective host immune
mechanisms observed after treatment with cyclo-
phosphamide result in an increased cell-mediated
immune response can be verified, and it should be
possible to demonstrate a cyclophosphamide-in-
duced repressor cell that modifies the activity of
suppressor cells induced by renal infection.
Chemical modification of antigens
Recent chemical modifications to antigens may
also allow the preferential induction of cell-mediat-
ed immune responses. Polymerization of bovine
serum albumin [38], the coupling of dodecanoic acid
[39], and the acetoacetylation of flagellin [40] all led
to a reduced capacity to elicit an antibody response
and to an enhanced cell-mediated immune re-
sponse. The demonstration that both soluble and
cell-bound antigens can be converted to prepara-
tions which induce cell-mediated immunity at the
expense of circulating antibody may have many
practical applications where the predominant host
immune mechanism has been shown to be the cell-
mediated immune response [41, 42].
Pharmacologic intervention in suppressor cell activity
One interesting possibility in the development of
therapeutic approaches to the management of renal
infection will be to identify the mechanism that en-
ables suppressor cells to modulate cell-mediated
immune function and attempt to block this activity
pharmacologically. Suppressor cells that develop
in response to antigenic challenge have been char-
acterized in animals [43] and in man [44] as glass-
adherent mononuclear cells that have many of the
characteristics of mononuclear phagocytic cells.
Macrophages can suppress cell-mediated immune
mechanisms [45], and although most of these effects
have been observed in vitro some have also been
confirmed in vivo [46, 47] and provide strong evi-
dence that macrophages have an immunoregulatory
role in intact animals. Examples of macrophage-me-
diated suppressor effects are common [48-50], and
several products of activated macrophages have
been identified that can inhibit the mitogenic re-
sponsiveness of lymphocytes [51-53]. Some of
these factors may be of significance only in vitro,
but the synthesis of prostaglandins, particularly the
pharmacologically active endoperoxide inter-
mediates, which have the potential to inhibit lym-
phocyte function, may well be biologically signifi-
cant. Evidence has accumulated that the prosta-
glandins, particularly PGE, through their action on
cyclic AMP are important regulators of immune
function [54-57] and that most agents which inhibit
mitogenic responses probably act by raising intra-
cellular levels of cyclic AMP [58, 59]. Both antigen-
ic and mitogenic challenges can stimulate prosta-
glandin synthesis in vitro and in vivo, and there is
evidence that activated macrophages synthesize
prostaglandin [60]. The prostaglandins could act in
vivo by triggering an "on-off" mechanism that pro-
vides the basis for a homeostatic effect regulating
the character and intensity of the inflammatory re-
sponse [61]. Thus, pharmacologic agents such as in-
domethacin, which inhibit prostaglandin synthe-
tase, have the potential to restore the prostaglandin-
induced depression of local effector lymphocyte re-
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sponses by blocking prostaglandin synthesis and
enhancing local immune responses.
Qualifying comments
One of the purposes of this editorial has been to
review evidence for the role of T lymphocytes in the
pathogenesis of renal infection. A problem in devel-
oping this concept has been to define how T lym-
phocytes exert their antimicrobial effect against E.
co/i. A possible mechanism is by the activation of
direct cytotoxic activity of the T lymphocytes, but
there is little supportive evidence that this mecha-
nism is effective against extracellular Gram-nega-
tive bacilli. A more likely explanation is the produc-
tion of lymphokines, which influence the activity of
macrophages. Depressed macrophage activity
would lead to a delayed and ineffective cellular re-
sponse. One difficulty in promoting the role of cell-
mediated immune mechanisms in renal infection is
that the course of the disease has not been influ-
enced by attempts to deplete animals of T lympho-
cytes [62, 63]. Absolute T lymphocyte depletion,
however, is difficult to achieve, and selective deple-
tion of subpopulations may leave sufficient effector
T cells to maintain immune function.
Despite these uncertainties, the data linking a
suppressor cell-associated depressed cell-mediated
immunity with the increased susceptibility of renal
tissue to infection form a coherent pattern. Evi-
dence for the direct involvement of cell-mediated
immune mechanisms in host resistance to renal in-
fection may come with an increased understanding
of the interaction of each component of the immune
system. We believe this concept is worth pursuing,
as it may well serve as a model for the control of
intractable infection by immunomanipulation.
THOMAS MILLER
DEREK NORTH
Auckland, New Zealand
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